Université Joseph Fourier , often known as UJF, is a French university situated in the city of Grenoble and focused on the fields of science, technologies and health. This institution was previously also called Université Grenoble I . Wikipedia.
Joseph Fourier University and French National Center for Scientific Research | Date: 2015-04-22
The present invention relates to novel NADPH oxidase, or Nox, proteins, to the use thereof, to a method for preparing same and to a method for identifying same.
French National Center for Scientific Research and Joseph Fourier University | Date: 2015-02-26
Multimenic lectins having a -propeller architecture, formed from monomer modules of approximately 30 to 60 amino acids, in which the binding sites to the glycans are situated on a given side of the proteins and the O-terminus and N-terminus ends of the peptide chains on the other side of the proteins, characterized in that they are formed from 4 to 7 monomer modules, a single, or a plurality of, or all of the adjacent modules being linked to one another by the linkers linking the N-terminus end of one module to the C-terminus end of the adjacent module.
Joseph Fourier University | Date: 2015-09-24
The invention relates to a method of processing a biological signal including peaks, said biological signal being recorded by at least one sensor, the method comprising:
University Grenobles Alpes and Joseph Fourier University | Date: 2017-01-03
A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and lasl in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become killed but metabolically active.
Joseph Fourier University | Date: 2017-04-12
A method and device for detecting a worsening of the cardio-respiratory condition of a patient treated using a respiratory assistance device comprising means for collecting and processing parameters indicative: - of a first parameter indicative of the breathing rate in a first observation window; - of a second parameter indicative of the percentage of cycles initiated by the patient during a second observation window; - of a third parameter indicative of the duration of use of the apparatus during a third observation window. The method is characterized in that it involves detecting a significant variation in one of said parameters over at least two consecutive or non-consecutive days during a consecutive period of n days, where n is strictly greater than 3 and preferably greater than or equal to 5; and, in response to said detection, generating an alert intended for said patient or for a practitioner in order to inform same of a significant risk of worsening of the cardio-respiratory condition of the patient.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 28.14M | Year: 2016
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 24.09M | Year: 2015
HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous primeboost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the risk curve in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETPROACT-01-2016 | Award Amount: 8.65M | Year: 2016
The goal of BrainCom is to develop a new generation of neuroprosthetic devices for large-scale and high density recording and stimulation of the human cortex, suitable to explore and repair high-level cognitive functions. Since one of the most invalidating neurospychological conditions is arguably the impossibility to communicate with others, BrainCom primarily focuses on the restoration of speech and communication in aphasic patients suffering from upper spinal cord, brainstem or brain damage. To target broadly distributed neural systems as the language network, BrainCom proposes to use novel electronic technologies based on nanomaterials to design ultra-flexible cortical and intracortical implants adapted to large-scale high-density recording and stimulation. The main challenge of the project is to achieve flexible contact of broad cortical areas for stimulation and neural activity decoding with unprecedented spatial and temporal resolution. Critically, the development of such novel neuroprosthetic devices will permit significant advances to the basic understanding of the dynamics and neural information processing in cortical speech networks and the development of speech rehabilitation solutions using innovative brain-computer interfaces. Beyond this application, BrainCom innovations will enable the study and repair of other high-level cognitive functions such as learning and memory as well as other clinical applications such as epilepsy monitoring using closed-loop paradigms. BrainCom will be carried out by a consortium assembled to foster the emergence of a new community in Europe acting towards the development of neural speech prostheses. Thanks to its high interdisciplinarity involving technology, engineering, biology, clinical sciences, and ethics, BrainCom will contribute advances to all levels of the value chain: from technology and engineering to basic and language neuroscience, and from preclinical research in animals to clinical studies in humans.
Agency: European Commission | Branch: H2020 | Program: ERC-ADG | Phase: ERC-ADG-2014 | Award Amount: 2.40M | Year: 2016
Cryptology is a foundation of information security in the digital world. Todays internet is protected by a form of cryptography based on complexity theoretic hardness assumptions. Ideally, they should be strong to ensure security and versatile to offer a wide range of functionalities and allow efficient implementations. However, these assumptions are largely untested and internet security could be built on sand. The main ambition of Almacrypt is to remedy this issue by challenging the assumptions through an advanced algorithmic analysis. In particular, this proposal questions the two pillars of public-key encryption: factoring and discrete logarithms. Recently, the PI contributed to show that in some cases, the discrete logarithm problem is considerably weaker than previously assumed. A main objective is to ponder the security of other cases of the discrete logarithm problem, including elliptic curves, and of factoring. We will study the generalization of the recent techniques and search for new algorithmic options with comparable or better efficiency. We will also study hardness assumptions based on codes and subset-sum, two candidates for post-quantum cryptography. We will consider the applicability of recent algorithmic and mathematical techniques to the resolution of the corresponding putative hard problems, refine the analysis of the algorithms and design new algorithm tools. Cryptology is not limited to the above assumptions: other hard problems have been proposed to aim at post-quantum security and/or to offer extra functionalities. Should the security of these other assumptions become critical, they would be added to Almacrypts scope. They could also serve to demonstrate other applications of our algorithmic progress. In addition to its scientific goal, Almacrypt also aims at seeding a strengthened research community dedicated to algorithmic and mathematical cryptology.
De Pape G.,Joseph Fourier University
Annual Review of Physical Chemistry | Year: 2012
Solid-state nuclear magnetic resonance (SSNMR) magic angle spinning (MAS) can be used to record high-resolution data dominated by site-specific information. Although MAS introduces high resolution by attenuating the anisotropic broadening, it also suppresses the nuclear dipole-dipole distance information that is the source of most structural data in the spectra. Such information can be reintroduced coherently and thus selectively by the application of a carefully chosen sequence of radiofrequency pulses, an approach that was introduced 20 years ago and is referred to as dipolar recoupling. This review presents the establishment of recoupling techniques in SSNMR and recalls the major steps achieved by the community throughout the last two decades. This review also presents emerging techniques and their corresponding new concepts. Finally, we present some recent developments based on second-order recoupling mechanisms and discuss their implications regarding dipolar truncation and the possibility to extract structural constraints in uniformly labeled systems. © Copyright ©2012 by Annual Reviews. All rights reserved.